Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
Pharmacoeconomics
.
2023 May;41(5):605.
doi: 10.1007/s40273-023-01263-w.
Authors
Hardik Goswami
1
2
,
Adnan Alsumali
3
,
Yiling Jiang
4
,
Matthias Schindler
5
,
Elizabeth R Duke
6
,
Joshua Cohen
7
,
Andrew Briggs
8
,
Amy Puenpatom
3
Affiliations
1
BARDS-Health Economics and Decision Science, Merck & Co, Inc., Kenilworth, NJ, USA. hardik.goswami@merck.com.
2
BARDS-Health Economics and Decision Science, Merck & Co, Inc., 770 Sumneytown Pike, West Point, PA, 19486, USA. hardik.goswami@merck.com.
3
BARDS-Health Economics and Decision Science, Merck & Co, Inc., Kenilworth, NJ, USA.
4
BARDS-Health Economics and Decision Science MSD (UK) Ltd, London, UK.
5
BARDS-HTA, MSD Ltd, Zurich, Switzerland.
6
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
7
Center for the Evaluation of Value and Risk in Health, Boston, MA, USA.
8
London School of Hygiene and Tropical Medicine, London, UK.
PMID:
36928836
PMCID:
PMC10019393
DOI:
10.1007/s40273-023-01263-w
No abstract available
Publication types
Published Erratum